Search
Veracyte Inc
VCYTAdd to Watchlist
38.480USD
-0.420-1.08%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
3.07BMarket Cap
34.51P/E TTM
More Details of Veracyte Inc Company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Veracyte Inc Info
Ticker SymbolVCYT
Company nameVeracyte Inc
IPO dateOct 30, 2013
CEOStapley (Marc A)
Number of employees824
Security typeOrdinary Share
Fiscal year-endOct 30
Address6000 Shoreline Court, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502436300
Websitehttps://www.veracyte.com/
Ticker SymbolVCYT
IPO dateOct 30, 2013
CEOStapley (Marc A)
Company Executives of Veracyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
151.41K
-24.55%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.13K
+4.05%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
41.87K
+21.64%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
32.11K
-60.63%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
32.06K
-43.95%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
29.99K
+7.18%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
20.04K
+10.74%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
17.88K
+12.04%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
17.82K
-60.65%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
4.23K
+50.84%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
151.41K
-24.55%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.13K
+4.05%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
41.87K
+21.64%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
32.11K
-60.63%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
32.06K
-43.95%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
29.99K
+7.18%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
496.60M
96.03%
International
20.55M
3.97%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.43%
Artisan Partners Limited Partnership
6.89%
State Street Investment Management (US)
6.32%
Fidelity Management & Research Company LLC
6.12%
Vanguard Portfolio Management, LLC
5.57%
Other
60.68%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.43%
Artisan Partners Limited Partnership
6.89%
State Street Investment Management (US)
6.32%
Fidelity Management & Research Company LLC
6.12%
Vanguard Portfolio Management, LLC
5.57%
Other
60.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor
64.19%
Investment Advisor/Hedge Fund
34.77%
Hedge Fund
5.42%
Research Firm
3.29%
Pension Fund
1.56%
Bank and Trust
0.60%
Individual Investor
0.57%
Holding Company
0.17%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
683
96.10M
120.44%
-1.89M
2025Q4
654
89.69M
113.46%
-3.72M
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
11.51M
14.49%
+194.38K
+1.72%
Dec 31, 2025
Artisan Partners Limited Partnership
6.26M
7.88%
-1.11M
-15.03%
Dec 31, 2025
State Street Investment Management (US)
4.36M
5.49%
+161.24K
+3.84%
Dec 31, 2025
Fidelity Management & Research Company LLC
4.88M
6.14%
-869.86K
-15.13%
Dec 31, 2025
ARK Investment Management LLC
3.89M
4.89%
-578.23K
-12.95%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
2.80M
3.52%
-317.69K
-10.19%
Dec 31, 2025
Wellington Management Company, LLP
2.04M
2.56%
-1.34M
-39.63%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.90M
2.39%
+9.43K
+0.50%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
4.35%
ARK Genomic Revolution ETF
3.68%
First Trust NYSE Arca Biotechnology Index Fund
3.48%
Global X Genomics & Biotechnology ETF
3.13%
ROBO Global Healthcare Technology & Innovation ETF
2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
1.97%
Invesco S&P SmallCap Health Care ETF
1.74%
Franklin Genomic Advancements ETF
1.45%
ROBO Global Artificial Intelligence ETF
1.43%
ARK Innovation ETF
1.24%
View more
Invesco Biotechnology & Genome ETF
Proportion4.35%
ARK Genomic Revolution ETF
Proportion3.68%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.48%
Global X Genomics & Biotechnology ETF
Proportion3.13%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.97%
Invesco S&P SmallCap Health Care ETF
Proportion1.74%
Franklin Genomic Advancements ETF
Proportion1.45%
ROBO Global Artificial Intelligence ETF
Proportion1.43%
ARK Innovation ETF
Proportion1.24%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
